The goal of project 2 is to investigate the role of lipoprotein lipase (LPL) in lipoprotein metabolism, energy homeostasis and atherogenesis. The experimental approach will center on establishing a line of LPL knockout mice which will be cross-bred with transgenic mice expressing both LPL in a tissue specific manner and/or other genes involved in lipoprotein and energy metabolism. LPL is one of the key lipoprotein modifying enzymes, catalyzing the hydrolysis of triglyceride rich lipoproteins, and therefore this project is directly related to the theme of the program project grant - namely, the investigation of lipoprotein metabolism and atherogenesis using tissue culture and genetically manipulated mice.
The specific aims of this project are: (1) to rescue the LPL deficient mouse and thereby establish a line to study LPL functions as well as the biochemical and physiological consequences of LPL deficiency, (2) to create transgenic mice that selectively express LPL in a tissue specific manner to study the role of LPL in the tissue distribution of calories and int he determination of body mass composition, and (3) to assess the role of LPL in atherosclerosis. These studies will involve extensive interaction with ?he transgenic core facility as well as projects 1 and 5. The results of these studies will provide new information regarding the role and importance of LPL in both lipoprotein metabolism and, more generally, in energy homeostasis. In particular, information gained from aim 2 will directly address hypotheses implicating LPL ina the development of obesity and cachexia.
Aim 3 will develop and use methods to specifically assess macrophage LPL and thus, will determine the role of macrophage LPL in the pathogenesis of atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL054591-01
Application #
3737359
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications